|
| 36049028 | Liver Inflammation Is Common and Linked to Metabolic Derangements in Persons With Treated Human Immunodeficiency Virus (HIV). | Clin Infect Dis | 2023 |
| 37548977 | Aging-Related Comorbidity Burden Among Women and Men With or At-Risk for HIV in the US, 2008-2019. | JAMA Netw Open | 2023 |
| 37579203 | Direct-Acting Antiviral Therapy for Treatment of Acute and Recent Hepatitis C Virus Infection: A Narrative Review. | Clin Infect Dis | 2023 |
| 35686432 | The Effect of Menopausal Status, Age, and Human Immunodeficiency Virus (HIV) on Non-AIDS Comorbidity Burden Among US Women. | Clin Infect Dis | 2023 |
| 37191706 | Fluvoxamine vs Placebo and Time to Recovery in Outpatients With Mild to Moderate COVID-19-Reply. | JAMA | 2023 |
| 37116583 | Transplanting hepatitis B surface antigen-positive livers in the United States: Outcomes and opportunities. | Am J Transplant | 2023 |
| 37435958 | Lessons From COVID-19 for Pandemic Preparedness: Proceedings From a Multistakeholder Think Tank. | Clin Infect Dis | 2023 |
| 37328184 | Safety and efficacy of hydroxychloroquine as prophylactic against COVID-19 in healthcare workers: a meta-analysis of randomised clinical trials. | BMJ Open | 2023 |
| 36740039 | Antiviral Treatment Failures After Transplantation of Organs From Donors With Hepatitis C Infection: A Report of 4 Cases. | Am J Kidney Dis | 2023 |
| 36682681 | Hydroxychloroquine for pre-exposure prophylaxis of COVID-19 in health care workers: a randomized, multicenter, placebo-controlled trial Healthcare Worker Exposure Response and Outcomes of Hydroxychloroquine (HERO-HCQ). | Int J Infect Dis | 2023 |
| 36633838 | Effect of Fluvoxamine vs Placebo on Time to Sustained Recovery in Outpatients With Mild to Moderate COVID-19: A Randomized Clinical Trial. | JAMA | 2023 |
| 36221143 | Improved Survival After Liver Transplantation for Patients With Human Immunodeficiency Virus (HIV) and HIV/Hepatitis C Virus Coinfection in the Integrase Strand Transfer Inhibitor and Direct-Acting Antiviral Eras. | Clin Infect Dis | 2023 |
| 33069882 | Expert Panel Review on Nonalcoholic Fatty Liver Disease in Persons With Human Immunodeficiency Virus. | Clin Gastroenterol Hepatol | 2022 |
| 35365841 | COVID-19 Trials: Who Participates and Who Benefits? | South Med J | 2022 |
| 36751648 | Cumulative Human Immunodeficiency Virus (HIV)-1 Viremia Is Associated With Increased Risk of Multimorbidity Among US Women With HIV, 1997-2019. | Open Forum Infect Dis | 2022 |
| 36593621 | Secondary hemophagocytic lymphohistiocytosis due to Heartland virus. | BMJ Case Rep | 2022 |
| 36561174 | Effect of Ivermectin 600 μg/kg for 6 days vs Placebo on Time to Sustained Recovery in Outpatients with Mild to Moderate COVID-19: A Randomized Clinical Trial. | medRxiv | 2022 |
| 36269852 | Effect of Ivermectin vs Placebo on Time to Sustained Recovery in Outpatients With Mild to Moderate COVID-19: A Randomized Clinical Trial. | JAMA | 2022 |
| 36299427 | Fluvoxamine for Outpatient Treatment of COVID-19: A Decentralized, Placebo-controlled, Randomized, Platform Clinical Trial. | medRxiv | 2022 |
| 35982669 | Ivermectin for Treatment of Mild-to-Moderate COVID-19 in the Outpatient Setting: A Decentralized, Placebo-controlled, Randomized, Platform Clinical Trial. | medRxiv | 2022 |
| 35982649 | Inhaled Fluticasone for Outpatient Treatment of Covid-19: A Decentralized, Placebo-controlled, Randomized, Platform Clinical Trial. | medRxiv | 2022 |
| 36259068 | Development and evaluation of a novel training program to build study staff skills in equitable and inclusive engagement, recruitment, and retention of clinical research participants. | J Clin Transl Sci | 2022 |
| 35026142 | A minimal monitoring approach for the treatment of hepatitis C virus infection (ACTG A5360 [MINMON]): a phase 4, open-label, single-arm trial. | Lancet Gastroenterol Hepatol | 2022 |
| 32115628 | The Prevalence and Burden of Non-AIDS Comorbidities Among Women Living With or at Risk for Human Immunodeficiency Virus Infection in the United States. | Clin Infect Dis | 2021 |
| 33859192 | Mortality outcomes with hydroxychloroquine and chloroquine in COVID-19 from an international collaborative meta-analysis of randomized trials. | Nat Commun | 2021 |
| 34712863 | A randomized, double-blind, placebo-controlled clinical trial of fluconazole as early empiric treatment of coccidioidomycosis pneumonia (Valley Fever) in adults presenting with community-acquired pneumonia in endemic areas (FLEET-Valley Fever). | Contemp Clin Trials Commun | 2021 |
| 33990619 | Author Correction: Mortality outcomes with hydroxychloroquine and chloroquine in COVID-19 from an international collaborative meta-analysis of randomized trials. | Nat Commun | 2021 |
| 34371163 | Design of the Healthcare Worker Exposure Response and Outcomes (HERO) research platform. | Contemp Clin Trials | 2021 |
| 33378562 | Proton pump inhibitor usage reduces sustained viral response rates for veterans with HIV/HCV coinfection on ledipasvir/sofosbuvir: a real-world study from a multicentre VA cohort. | J Viral Hepat | 2021 |
| 33085923 | New Therapeutics for Hepatitis B: The Road to Cure. | Annu Rev Med | 2021 |
| 33104186 | COVID-19-Lessons Learned and Questions Remaining. | Clin Infect Dis | 2021 |
| 33388773 | Incident Non-AIDS Comorbidity Burden Among Women With or at Risk for Human Immunodeficiency Virus in the United States. | Clin Infect Dis | 2021 |
| 32406244 | Standard Versus Extended Duration Direct-Acting Antiviral Therapy in Hepatitis C Patients With Slow Response to Treatment. | Ann Pharmacother | 2020 |
| 31803945 | A Randomized Controlled Trial of an Integrated Alcohol Reduction Intervention in Patients With Hepatitis C Infection. | Hepatology | 2020 |
| 31829433 | Ombitasvir/paritaprevir/ritonavir and dasabuvir±ribavirin for chronic HCV infection in US veterans with psychiatric disorders. | J Med Virol | 2020 |
| 31881361 | Increased Glutaminolysis Marks Active Scarring in Nonalcoholic Steatohepatitis Progression. | Cell Mol Gastroenterol Hepatol | 2020 |
| 33245351 | Direct-Acting Antiviral Therapy for Hepatitis C Virus Infection: Fulfilling the Potential on the Road to Elimination. | J Infect Dis | 2020 |
| 32995348 | Cardiovascular Disease Risk Management in Persons With HIV: Does Clinician Specialty Matter? | Open Forum Infect Dis | 2020 |
| 32701942 | Testing and Clinical Management of Health Care Personnel Potentially Exposed to Hepatitis C Virus - CDC Guidance, United States, 2020. | MMWR Recomm Rep | 2020 |
| 32502252 | Metabolomic Signature as a Predictor of Liver Disease Events in Patients With HIV/HCV Coinfection. | J Infect Dis | 2020 |
| 30697570 | Correlation Between Tenofovir Drug Levels and the Renal Biomarkers RBP-4 and ÿ2M in the ION-4 Study Cohort. | Open Forum Infect Dis | 2019 |
| 31643035 | Nonalcoholic Fatty Liver Disease Among Individuals with HIV Mono-infection: A Growing Concern? | Dig Dis Sci | 2019 |
| 31685570 | Hepatitis C Behind and Beyond Bars: Targeting the US Prison Population and Changing North Carolina Prisoner Health Policy. | N C Med J | 2019 |
| 30058111 | Using Stepwise Pharmacogenomics and Proteomics to Predict Hepatitis C Treatment Response in Difficult to Treat Patient Populations. | Proteomics Clin Appl | 2019 |
| 31371060 | Global Longitudinal Strain and Immune Status in Patients Living With Human Immunodeficiency Virus. | Am J Cardiol | 2019 |
| 31220220 | Ledipasvir/Sofosbuvir for 8 Weeks to Treat Acute Hepatitis C Virus Infections in Men With Human Immunodeficiency Virus Infections: Sofosbuvir-Containing Regimens Without Interferon for Treatment of Acute HCV in HIV-1 Infected Individuals. | Clin Infect Dis | 2019 |
| 31099822 | Management of Hepatitis C in 2019. | JAMA | 2019 |
| 30976736 | Sustained Virologic Response in People Who Inject Drugs and/or Who Are on Opioid Agonist Therapy: Is 90% Enough? | Hepatol Commun | 2019 |
| 30641483 | Treating HCV Infection: It Doesn't Get Much Better Than This. | Top Antivir Med | 2019 |
| 29193564 | IFN-free therapy is associated with restoration of type I IFN response in HIV-1 patients with acute HCV infection who achieve SVR. | J Viral Hepat | 2018 |